mTOR/S6K1 regulates the SREBP-1c signaling pathway through LXRα in sodium palmitate-induced HepG2 cells, suggesting LXRα might be a potential therapeutic target for NAFLD. Here, RPS6KB1 is linked to metabolic dysfunction-associated steatotic liver disease.